Friday, September 12, 2025

Latest

Psyched Wellness Adds Amanita Muscaria Expert To Advisory Board

Kevin Feeney has joined the advisory board of that of Psyched Wellness (CSE: PSYC) as of this morning. Feeney will be working with the company to identify novel uses for the psychoactive constituent in Amanita Muscaria, which is known as Muscimol.

Feeny is a cultural anthropologist and lawyer, whom current serves as program director as well as an instructor in interdisciplinary studies – social sciences at the Central Washington University. Viewed as an expert on the Amanita muscaria mushroom, his primary research is focused on examining legal and regulatory issues that surround psychoactive substances, as well as exploring both the modern and traditional uses of these unique species of mushrooms.

Furthermore, Feeney, whom has a PhD in cultural anthropology, has many publications to his name, including an edited volume on amanita muscaria within Fly Agaric: A Compendium of History, Pharmacology, Mythology, and Exploration, while having also been published in the Journal of Psychoactive Drugs and the International Journal of Drug Policy among others.

Commenting on his appointed as scientific advisor to Psyched Wellness, Feeney stated, “Amanita Muscaria has a long history of use for treating a number of ailments including anxiety, insomnia, pain, and inflammation. While this mushroom has been largely overlooked in both standard and alternative medicines, its potential applications are rich and largely unexplored, and shows promise in such disparate areas as treating alcohol and benzodiazepine withdrawal as well as alleviating cognitive impairments related to Lyme disease and Alzheimer’s.”

The addition to the board of advisors is seen as being a key development within the growth of the company. The experience brought forth by Feeny is expected to assist the company in identifying new novel uses of the compound, in applications for health and wellness.

Psyched Wellness last traded at $0.195 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Avino Q2 Earnings: Steady As She Goes

MEG Energy: Cenovus Comes In With $7.9 BILLION Offer

Orla Mining Q2 Earnings: Musselwhite Changes Everything

Recommended

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Goliath Resources Hits 18.58 g/t Gold Over 5.00 Metres At Surebet

Related News

Psyched Wellness Sees Positive Results From Amanita Muscaria Toxicology Report

Psyched Wellness (CSE: PSYC) has completed its toxicology assessment on that of Amanita Muscaria, the...

Monday, December 7, 2020, 07:56:50 AM

Psyched Wellness Launches Study On Mushroom Extract Focused On Gut Health

Psyched Wellness (CSE: PSYC) this morning issued a very brief press release related to ongoing...

Tuesday, March 30, 2021, 08:31:58 AM

Psyched Wellness Announces Study On Muscimol Antioxidant and Anti-Inflammatory Properties

Psyched Wellness (CSE: PSYC) has begun yet another study related to that of the Amanita...

Wednesday, January 6, 2021, 07:48:08 AM

Psyched Wellness Commences 90-Day Toxicity Study Of AME-1

Psyched Wellness (CSE: PSYC) continues to progress on its preclinical studies for its novel mushroom...

Monday, June 28, 2021, 08:55:03 AM

Psyched Wellness Increases Bought Deal To $5.5 Million

Psyched Wellness (CSE: PSYC) has increased the size of its bought deal private placement as...

Monday, January 25, 2021, 07:09:05 AM